Echolucent carotid artery plaques are associated with elevated levels of fasting and postprandial triglyceride-rich lipoproteins

Stroke

Volumn 27, Issue 12, 1996, Pages 2166-2172

  Grønholdt, Marie Louise Moes ^a,b   Nordestgaard, Børge G ^a   Nielsen, Tina G ^a   Sillesen, Henrik ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b University of Copenhagen   (Denmark)

Author keywords

arteriosclerosis; carotid artery diseases; lipoproteins; ultrasonics

Indexed keywords

CHYLOMICRON; LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; ATHEROSCLEROTIC PLAQUE; B SCAN; BODY MASS; CAROTID ARTERY OBSTRUCTION; DIET RESTRICTION; FEMALE; HUMAN; LIPID DIET; MAJOR CLINICAL STUDY; MALE; POSTPRANDIAL STATE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030455607     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.27.12.2166     Document Type: Article

References (41)

1. Pyörälä K, Backer GD, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 1994;15:1300-1331.
2. Carleton RA, Chairman P, Dwyer J, Finberg L, Flora J, Goodman DWS, Grundy SM, Havas S, Hunter GT, Kritchevsky D, Lauer RM, Luepker RV, Ramirez AG, Horn LV, Stason WB, Stokes J 3rd. Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction: a statement from the National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health. Circulation. 1991;83:2154-2232.
3. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
4. Brown G, Albers JJ, Fisher LD, Schaeffer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990; 323:1289-1298.
5. Blankenhorn DH, Azen SP, Crawford DW, Nessim SA, Sanmarco ME, Selzer RH, Shircore AM, Wickham EC. Effects of colestipolniacin therapy on human femoral atherosclerosis. Circulation. 1991; 83:438-447.
6. Blankenhorn DH, Selzer RH, Crawford DW, Barth JD, Liu C, Liu C, Mack WJ, Alaupovic P. Beneficial effects of colestipol-niacin therapy on the common carotid artery: two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation. 1993;88:20-28.
7. Furberg CD, Adams HP, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, Young B, for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Effects of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994; 90:1679-1687.
8. Crouse JR 3rd, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol. 1995;75:455-459.
9. Salonen R, Nyyssönen K, Porkkala E, Rummukainen J, Belder R, Park JS, Salonen JT. Kuopio Atherosclerosis Prevention Study (KAPS): a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 1995;92:1758-1764.
10. Scandianvian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1383-1389.
11. Shephard J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333:1301-1307.
12. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260:641-651.
13. Blankenhorn DH, Kramsch DM. Reversal of atherosis and sclerosis: the two components of atherosclerosis. Circulation. 1989;79:1-7.
14. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87: 1781-1791.
15. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
16. European Carotid Plaque Study Group. Carotid artery plaque composition: relationship to clinical presentation and ultrasound B-mode imaging. Eur J Vasc Endovasc Surg. 1995;10:23-30.
17. Langsfield M, Gray-Weale AC, Lusby RJ. The role of plaque morphology and diameter reduction in the development of new symptoms in asymptomatic carotid arteries. J Vasc Surg. 1989;9:548-557.
18. Johnson JM, Kennelly MM, Decesare D, Morgan S, Sparrow A. Natural history of asymptomatic carotid plaque. Arch Surg. 1985;120: 1010-1012.
19. Sterpetti AV, Schultz RD, Feldhaus RJ, Davenport KL, Richardson M, Farina C, Hunter WJ. Ultrasonographic features of carotid plaque and the risk of subsequent neurologic deficits. Surgery. 1988;104: 652-660.
20. Londrey GL, Spadone DP, Hodgson KJ, Ramsey DE, Barkmeier LD, Sumner DS. Does color-flow imaging improve the accuracy of duplex carotid evaluation? J Vasc Surg. 1991;13:659-662.
21. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal. J Lipid Res. 1988;29:925-936.
22. Rossi E, Mondonico P, Lombardi A, Preda L. Method for the determination of functional (clottable) fibrinogen by the new family of ACL coagulometers. Thromb Res. 1988;52:453-468.
23. Statistica for Windows. Tulsa, Okla: Stat Soft, Inc; 1994:1-3911,
24. Geroulakos G, Ramaswami G, Nicolaides A, James K, Labropoulos N, Belcaro G, Holloway M. Characterization of symptomatic and asymptomatic carotid plaques using high-resolution real-time ultrasonography. Br J Surg. 1993;80:1274-1277.
25. Feeley TM, Leen EJ, Colgan MP, Moore DJ, Hourihane DOB, Shanik GD. Histologic characteristics of carotid artery plaque. J Vasc Surg. 1991;13:719-724.
26. Strandness DE. Extracranial arterial disease. In: Strandness DE, ed. Duplex Scanning in Vascular Disorders. New York, NY: Raven Press; 1990:92-121.
27. Ryu JE, Howard G, Craven TE, Bond MG, Hagaman AP, Crouse JR 3d. Postprandial triglyceridemia and carotid atherosclerosis in middle-aged subjects. Stroke. 1992;23:823-828.
28. Simpson HS, Williamson CM, Olivacrona T, Pringle S, Maclean J, Lorimer AR, Bonnefous F, Bogaievsky Y, Packard CJ, Shephard J. Postprandial lipemia, fenofibrate and coronary artery disease. Arteriosclerosis. 1990;85:193-202.
29. Groot PHE, van Stiphout WAHJ, Krauss XH, Jansen H, van Tol A, van Ramshorst E, Chin-On S, Hofman A, Cresswell SR, Havekes L. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb. 1991;11: 653-662.
30. Patsch JR, Miesenböck G. Hopferwieser T, Mühlberger V, Knapp E, Dunn JK, Gotto AM Jr, Patsch W. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb. 1992;12:1336-1345.
31. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis. 1994;106:83-97.
32. Nikkila M, Solakivi T, Lehtimaki T, Koivula T, Laippala P, Astrom B. Postprandial plasma lipoprotein changes in relation to apolipoprotein E phenotypes and low density lipoprotein size in men with and without coronary artery disease. Atherosclerosis. 1994;106:149-157.
33. Conn JS. Postprandial lipid metabolism. Curr Opin Lipidol. 1994; 5:185-190.
34. Karpe F, Hamsten A. Postprandial lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 1995;6:123-129.
35. Zilversmit DB. Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins. Clin Chem. 1995;41:153-158.
36. Nordestgaard BG, Zilversmit DB. Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits. J Lipid Res. 1988;29:1491-1500.
37. Nordestgaard BG, Nielsen LB. Atherosclerosis and arterial influx of lipoproteins. Curr Opin Lipidol. 1994;5:252-257.
38. Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo: molecular size as a determinant of fractional loss from the intimainner media. Arterioscler Thromb Vasc Biol. 1995;15:534-542.
39. Rapp JH, Lespine A, Hamilton RL, Colyvas N, Chaumeton AH, Tweedie-Hardman J, Kotite L, Kunitake ST, Havel RJ, Kane JP. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb. 1994;14:1767-1774.
40. Bradley WA, Gianturco SH. Triglyceride-rich lipoproteins and atherosclerosis: pathophysiological considerations. J Intern Med. 1994; 236(suppl 736):33-39.
41. Brown SA, Chambless LE, Sharrett AR, Gotto AM Jr, Patsch W. Postprandial lipemia: reliability in an epidemiologic field study. Am J Epidemiol. 1992;136:538-545.